title: Propranolol for infantile haemangiomas: a review.
abstract: Infantile haemangiomas are the most common benign tumour of infancy. However the majority are self-resolving and only a small minority of cases require treatment, with various different medications being used in the past. Over the last few years, propranolol, a non-selective β-blocker, has become a popular and successful treatment for infantile haemangiomas. However, further research on its safety is needed if it is going to be used more frequently. This article summarises the current literature on propranolol for haemangioma treatment with emphasis on its toxicity and adverse event profile.
authors.affiliation: Derbyshire Children's Hospital, Uttoxeter Road, Derby DE22 3NE, UK. elizabeth.starkey@nhs.net
authors.forename: E
authors.initials: E
authors.lastname: Starkey
authors.forename: H
authors.initials: H
authors.lastname: Shahidullah
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002675:Child, Preschool; D004334:Drug Administration Schedule; D006391:Hemangioma / Q000188:drug therapy* / Q000453:epidemiology; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D011433:Propranolol / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D000319:Adrenergic beta-Antagonists; D011433:Propranolol